Today's Veterinary Practice

JAN-FEB 2018

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link:

Contents of this Issue


Page 44 of 101

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2017 Zoetis Services LLC. All rights reserved. CYT-00097R1 Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs. *Repeat administration every 4 to 8 weeks, as needed, in individual patients. 1 References: 1. Data on fi le, Study Report No. C863R-US-12-018, Zoetis Inc. 2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x. 3. Data on fi le, Study Report No. C362N-US-13-042, Zoetis Inc. 4. Data on fi le, Study Report No. C961R-US-13-051, Zoetis Inc. Vet Dermatol . 2013;24(1):48-53. Data on fi le, Study Report No. C362N-US-13-042, Zoetis Inc. 4. Data on fi le, WEEKS OF RELIEF 1 * 4 - 8 4 8 - CYTOPOINT ® provides fast, eff ective relief that helps improve the long-term quality of life for dogs with atopic dermatitis and their families 1 TARGETED Targets and neutralizes interleukin (lL)-31, a key itch-inducing cytokine in atopic dermatitis 2 SAFE Safe for dogs of all ages, even those with concomitant diseases, and can be used with many common medications 3 ,4 WORKS FAST AND LASTS Begins working within 1 day and delivers 4 to 8 weeks of relief* from the clinical signs of atopic dermatitis; in-offi ce administration ensures compliance 1 To learn more, please visit FROM ITCHY AND ANGRY TO IZZY AND ANGIE CELEBRATING ONE YEAR OF ITCH-FREE HOLIDAYS... AND EVERYDAYS!

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - JAN-FEB 2018